Coherus Oncology dismisses EY, names PwC as new auditor
Share
Listen to the news
Coherus Oncology dismisses EY, names PwC as new auditor
  • Coherus Oncology’s audit committee dismissed Ernst & Young as independent auditor, effective June 12, 2026.
  • PwC was selected as the new auditor for the fiscal year ending Dec. 31, 2026, subject to standard client acceptance.
  • EY audit reports for 2025 and 2024 carried no adverse opinion, disclaimer, or qualification.
  • No accounting or audit-scope disputes were reported with EY through June 12, 2026.
  • A previously disclosed 2024 material weakness tied to inventory reconciliation documentation was reported remediated in 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coherus Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-074090), on June 15, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending